Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Patient Selection For Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.
EP: 1.Living with Type 1 Diabetes
EP: 2.Screening Guidelines for Type 1 Diabetes
EP: 3.Stages and Symptoms of Type 1 Diabetes
EP: 4.Impact of Delayed Intervention in Stage 2 Type 1 Diabetes
EP: 5.Types of Antibody Screening Tests for Type 1 Diabetes
EP: 6.Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Now Viewing
EP: 7.Patient Selection For Teplizumab and Infusion Process
EP: 8.Final Thoughts on Identifying and Managing Patients with T1D
Related Videos
Related Content
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
October 27th 2025Article
After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
